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HIV AND COSTS OF HOSPITAL CARE
Cost of inpatient care for HIV-
positive patients AT Red Cross
Children’s Hospital, Cape Town
There is anecdotal evidence that certain categories of patients at Red Cross War Memorial Children’s Hospital (RCH) are
thought to be utilising more resources than others. Faced with an ever-increasing demand for care, shrinking budgets
and tough measures by government to force health managers to operate within budget, bold decisions need to be taken
regarding future admission policy. The aim of this retrospective record-based study was to assess the cost of inpatient
care for paediatric HIV-positive patients at RCH over a 1-year period (January - December 2001). The objectives were (i)
to determine the cost of inpatient care for paediatric HIV-positive patients; and (ii) to provide baseline data for health
managers to develop future admission policy and to plan for future needs in terms of management and budgetary
protocols.
Methods. The study population consisted of HIV-positive inpatients admitted to RCH. Information on patients’
demographic details, date and duration of admission, reason for admission, additional diagnosis, nutritional status,
laboratory investigations done, surgical procedures performed and medication prescribed were obtained from the
patient records. Direct costs were recorded for admissions (bed costs), X-rays, laboratory and surgical procedures. The
tariff fees charged for these services were obtained in consultation with management at RCH. 
Results. There were 16 032 admissions to RCH in 2001. Of these patients 616 (4%) were HIV+. A 25% random sample 
(N = 154) with a mean age of 1.75 years was analysed. Almost 80% were admitted with diarrhoea and vomiting and/or
chest problems. The mean number of previous admissions was 2.0. The most common conditions diagnosed clinically
were failure to thrive (64%), pneumonia (54%), gastroenteritis (43%), oral thrush (42%) and tuberculosis (22%). Over
half were found to be underweight for their age, 20% were marasmic and 87% suffered some form of malnutrition at
admission. HIV+ patients were 4.7 times more likely to die in hospital than HIV-ve patients. Their average length of stay
in hospital was 9 days, compared with 4 days for HIV-ve patients. HIV+ patients consumed 12%, 61% and 9% of the
total budgets allocated for antibiotics, antifungals and analgesics, respectively (7% of the total budget for medicines).
The average cost (direct cost) for each HIV+ inpatient amounted to R18 765.76. Admission (bed) costs formed the bulk
of this amount (84%) followed by laboratory costs (9%), medication (3%), surgical (2%) and X-rays (2%). Alarmingly,
HIV+ patients, who formed 4% of the total admissions, consumed 26% (R11.56 million) of the total budget for direct
treatment costs (R44.65 million).
Conclusion.  The current admission policies regarding HIV+ patients to RCH appear unsustainable, given the continued
high demand for care, an ever-increasing HIV pandemic, the non-availability of antiretroviral therapy, lower health
budgets and the continued inability of these patients to pay for health services. 
The prevalence of HIV infection in the Western Cape lags
behind that of the rest of the country and sub-Saharan
Africa.1,2 However, the prevalence rate for women attending
antenatal clinics in this province has almost doubled from
3.09% to 6.29% between 1996 and 1997,3 indicating a
significant increase in the rates of new infection of HIV.
This trend has continued (8.6% — Provincial Administration
of the Western Cape, annual antenatal survey results,
2001)3 and has major cost implications for public hospitals
that provide specialised care for paediatric HIV patients.
One simply has to look beyond the debate of government’s
failure to provide antiretrovirals to reduce mother-to-child
transmission of HIV and deal with the realities and cost
implications of providing care for children with HIV. This
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scenario must be seen in the context of a decision taken by
the National Department of Health to cut the budget for
highly specialised services by R50 million from 1 April
2002.4 It is envisaged that these cuts in the budget will be
more than quadrupled in the next 5 - 8 years. The
implications for Red Cross War Memorial Children’s
Hospital (RCH) are tremendous — it now has to provide
specialised quality care for growing numbers of paediatric
HIV-positive patients in an environment where financial
resources are constantly being reduced by government so
that other priority areas can also receive funding. 
The specialised care offered to paediatric HIV-positive
patients at RCH needs to be costed to provide
administrators of the hospital with detailed information as
to how much of the current budget is used up in providing
care for these patients. Future planning in terms of patient
admission protocols, laboratory services, length of stay in
hospital, medicine costs, surgical procedures, home-based
care initiatives and priorities for non-HIV patients will be
directly affected by this costing exercise and ultimately
administrators will have to make bold decisions on the best
way to spend scarce resources in providing quality care for
children admitted to RCH.
Most health economists and HIV/AIDS experts support the
view that antiretroviral (ARV) drugs are a cost-effective
alternative when compared with the costs of providing care
for infected infants who are born HIV positive.5 Havens et
al.6 investigated the lifetime cost of care for children with
HIV infection. Based on a median survival time of 120
months, the mean lifetime charges for hospital-based care
for children with HIV infection was approximately 
U$408 307. Their data suggested an extremely beneficial
economic impact of the implementation of CDC
recommendations for universal counselling and voluntary
testing of pregnant women, coupled with AZT treatment of
pregnant women with HIV infection and their newborn
infants to reduce perinatal mother-to-child transmission
(MTCT). In a similar study in the Cape Town Metropole,
Roux et al.7 investigated the burden and cost of inpatient
care for HIV-positive paediatric patients. They found that
106 (8.3%) HIV patients occupied these beds at the time of
the survey. Furthermore, 25% of the HIV-infected children
received oxygen, 46% received intravenous foods or drugs,
81% had some form of malnutrition and 46% were
underweight for their respective ages. Tuberculosis (TB) was
diagnosed in 20% of the HIV-positive children. This was a
higher prevalence than previously found in hospitalised
children in this region and was thought to be related to the
effect of immunodeficiency on susceptibility to TB. 
Based on a daily bed cost of R280 per day, the annualised
cost of paediatric beds for a constant number of 57 HIV-
positive inpatients was found to be R5 825 400. The
estimated lifetime hospitalisation cost for an infant
diagnosed at 13 months (the median age for acute
admissions in this study), surviving for 32 months from the
time of diagnosis and requiring 2.4 admissions per annum
for a mean of 11 days per admission, would cost R19 712
per infant (based on a paediatric bed cost of R280 per day).
In comparison, the cost of the MTCT Prevention Programme
in Khayelitsha, Cape Town, was calculated at between 
R624 520 and R810 520 per annum, based on a rate of 
5 000 births each year. The cost included serological
screening for infection, treatment for an expected 10% of
infected women according to the Thai regimen,8
Pneumocystis carinii pneumonia (PCP) prophylaxis, follow-
up serotesting at 15 months of age and formula milk feeds
up to age 6 months for infants at risk. On the basis of a
vertical transmission rate of 30% and an effective 50%
protection rate, the cost per infant protected from
infection lies between R8 326 and R10 806, which is much
more cost effective than the R19 712 per infant required
for care of paediatric inpatients in a specialised hospital. 
Hussey et al.9 examined the survival patterns of 193
children in Cape Town known to be vertically infected with
HIV. The median survival of children with HIV was 32
months from time of diagnosis (median age at diagnosis
was 5 months) and survival time was influenced by age and
disease severity. For children over the age of 12 months, the
cumulative proportion surviving 48 months was 78%. This
compares poorly with survival rates in developed countries
such as the USA (where an HIV-infected infant has 75%
chance of surviving in excess of 5 years) and Italy (70% of
perinatally infected children were alive at 6 years and 50%
at 9 years). The difference in survival times can be
attributed to availability and access to medical care, access
to ARV therapy and other supportive care often lacking in
developing countries. 
A recent count at the RCH10 revealed that toddlers with
AIDS occupied 25% of the general paediatric beds. The
authors questioned the logic of spending 25% of the
hospital’s scarce resources on treating an inevitably fatal
affliction, i.e. denying access to these patients to alleviate
the chronic shortage of hospital beds for children with
other diseases. 
The European Collaborative study11 that reported on the
hospitalisation of children born to HIV-infected women in
Europe found that uninfected children had 0.5 admissions
per 5 child years compared with 2.4 for infected children. It
was found that infected children were 4 times more likely
to be hospitalised than uninfected children of the same
age. Nearly 60% of the total inpatient days of HIV-infected
children occurred after AIDS diagnosis. This places a heavy
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burden on the health care system and has implications for
planning and admission protocols in resource-poor
countries. Medscheme, the country’s largest private
medical scheme administrator, undertook a number of
studies12 in which they demonstrated that the hospital
treatment arising from complications of AIDS-defining
illnesses was more expensive than providing double or
triple ARV therapy for the rest of the patient’s life.
Medscheme calculated that it cost R60 000 per annum
(average first 2 years) to manage a patient with HIV/AIDS
on double ARV therapy, R70 000 per annum for triple
therapy, and R230 000 per annum on patients who were
unmanaged (not receiving ARV therapy).
Studies done elsewhere in Africa13-15 report that drug costs
and consumption among paediatric HIV patients will
continue to increase, resulting in shortages of essential
medicines because of financial constraints, and that the
impact of AIDS in the sub-Saharan region will result in less
treatment available to all patients — those with AIDS and
those without AIDS. The clinical spectrum of HIV disease in
children is similar in most African studies where ARVs are
not available to infected patients. These include respiratory
infection, malnutrition, anaemia, diarrhoea, malaria,
meningitis, pneumonia and TB.16-18
In summary, the literature shows clear evidence of an
increasing burden of costs placed on institutions and
governments in developing countries where paediatric
inpatient care occurs in the continued absence of ARV
therapy.19 There is much evidence that MTCT programmes
reduce infection rates and the provision of ARV therapy is
more cost effective than treating unmanaged patients
symptomatically for the wide spectrum of disease
associated with paediatric HIV/AIDS. Alternatives such as
home-based care for HIV/AIDS patients have been shown
to reduce the medical utilisation costs of HIV/AIDS cost by
between 28% and 50%, depending on which stage of the
disease the patient is at.20 These are difficult times for
health planners in developing countries, and difficult
decisions will have to be made regarding future inpatient
admission protocols and management protocols for
paediatric HIV-positive patients admitted to financially
strapped tertiary hospitals for care.
To assess the cost of inpatient care for paediatric HIV-
positive patients at RCH.
■ To determine the cost of inpatient care for paediatric
HIV-positive patients over a 1-year period at RCH.
■ To provide baseline data for health planners to
develop/modify admission and management protocols
for patients with paediatric HIV.
■ To provide baseline data for health planners at RCH to
plan for future needs in terms of budget allocation for
the management of paediatric HIV-positive patients.
The study population included all paediatric HIV-positive
children admitted to RCH for inpatient care between
January and December 2001. HIV positivity was confirmed
by means of a laboratory test. Patients who had clinical
signs and symptoms strongly associated with HIV/AIDS
infection but whose serological status was unknown were
excluded from the study. Similarly, patients who tested
negative for HIV, were awaiting retest or had not been
tested because consent had been refused, were not
included in the study population. Another inclusion
criterion was that admission as an inpatient must have
occurred within the specified study period of January -




Item Source Additional notes
Amounts for budgets RCH Budget for 2001/2002 Supplied by financial
HIV+ statistics RCH Laboratory director for RCH
Patient admission Administration office
statistics
Medicine costs Hospital pharmacy Tender price list for 2001.
These amounts are much 
lower than RAMS tariffs 
X-ray costs RAMS schedule of fees 2001 These tariffs were used 
after consultation with 
department head
Admission costs High care/general ward RAMS fees for 2001
R1 685.30 per day
ICU R2 631.00 per day
Surgical costs RAMS schedule of fees Same as above
Laboratory costs BHF tariff fees for 2001 Same as above
TABLE I. TARIFF FEES AND OTHER DATA USED IN THIS STUDY
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sample of all paediatric HIV-positive inpatients was chosen
for inclusion into the study.
Information describing the patient’s demographic details,
date and duration of admission, reason for admission,
additional diagnosis, nutritional status, laboratory
investigations done, surgical procedures performed and
medication prescribed were obtained from patient records. 
Only the direct costs attributable to patient care were
recorded. The costs for occupation of a paediatric bed
(admission costs — high care and intensive care), laboratory
investigations, medication obtained at the hospital
pharmacy, X-ray costs and costs for surgical procedures
were recorded as direct costs for each patient. Tariff fees
charged for these services were obtained after broad
consultation with the medical superintendent, director of
finances for RCH, senior nursing staff, department
managers, and hospital administrators in charge of patient
billings. Table I provides more detail as to how figures used
in this costing exercise were obtained. Ethical approval for
this survey was obtained from the Ethics Committee of
RCH and Stellenbosch University.
Indirect costs such as personnel costs, physicians’ fees, etc.
were excluded from this cost analysis because of the
inherent difficulties of estimating such costs. Data analysis
was done using Microsoft Excel Data Analysis and Data
Analysis Plus software packages and results are presented
in the form of graphs, tables and free text. Statistical
analyses (p-values, t-tests, confidence intervals, means,
etc.) are fully described where applicable. The limitation of
this study was that direct costs attributable to patient care
was dependent on the quality and accuracy of information
recorded in the patient files selected for analysis in this
study. 
Table II provides a summary of the demographics of the
study population for this retrospective costing analysis.
Almost 80% of the patients (Fig. 1) were admitted to RCH
with either diarrhoea and vomiting (42%) or cough, fever
and/or chest problems (37%) as the main complaint. Fig. 2
shows that the majority of the patients (62.3%) had no
previous admissions to RCH, but over 25% of HIV+ patients
who had previous admissions were admitted two or more
times as inpatients. About 5% of HIV+ patients had
previously been admitted to RCH 5 or more times for in-
hospital care.
On examination at RCH, 64% of the cohort were found to
be below key developmental milestones for their age
(failure to thrive (FTT)) while over half (54%) of the HIV+
patients were diagnosed as having pneumonia (Fig. 3).
Other common conditions that were also diagnosed among
this cohort of patients included gastroenteritis (43%), oral
thrush (42%), nappy rash (32%), TB (22%), and anaemia
(12%).
Fig. 4 shows the nutritional status of HIV+ patients at the
time of admission to RCH. A large proportion were reported
to suffer from some form of malnutrition (87%) at the time
of admission. Over half of the study sample (53%) were
RESULTS
Fig. 1. Reason for admission to RCH (HIV+ paediatric patients).
Fig. 2. Number of previous admissions to RCH.
Fig. 3. Clinical diagnosis for HIV+ paediatric inpatients at RCH.
Medical admissions 8 614
Surgical admissions 7 418
Total inpatient admissions 16 032
No. of confirmed HIV+ inpatients 616
25% random sample for analysis N = 154
Percentage of HIV+ inpatients 
against total admissions 4%
Race Black =141 (91.6%) 
Coloured = 13 (8.4%)
Gender Male = 83 (53.2%)
Female = 72 (46.8%)
Mean (average) age 21 months 
(1.75 years)
Median age 14 months
(1.2 years)
TABLE II. PATIENT STATISTICS FOR RCH, 2001
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found to be underweight for their age at admission and
almost 20% were found to be marasmic. In terms of in-
hospital deaths, 8% of the HIV+ patients died during their
stay at RCH. Although this figure seems low, it becomes
significant when compared with the overall death rate at
RCH for the similar period (8% v. 1.7%) — this means that
HIV+ patients were 4.7 times more likely to die in hospital
than their HIV-ve counterparts.
Table III provides information on the average length of stay
in hospital for HIV+ patients versus all admissions to RCH.
It was found that HIV+ patients stayed in hospital more
than twice as long as the HIV-ve patients (9 v. 4.03 days).
MEDICATION COSTS FOR HIV+ INPATIENTS
Table IV provides a summary of the medication costs of
HIV+ inpatients at RCH.  Medicines were essentially used to
treat infections in these immunocompromised individuals
and for prophylactic cover against further infection. Table
V gives a  breakdown on the average cost per patient of
each of the groups of drugs costed, the budget available for
that group of drugs and the percentage of budget
consumed per group of drug by HIV+ patients admitted to
RCH.
Fig. 5 is a graphic representation of Table IV. 
Since HIV+ patients are prone to opportunistic infections, it
was expected that the use of antifungal drugs among these
patients would be high. However, it must be noted that
these patients, who comprised only 4% of the total number
of patients admitted to RCH in 2001, consumed 61% of the
budget allocated for the purchase of antifungal
medication. Similarly, they consumed 12%, 9% and 3% of
the budgets allocated for antibiotics, analgesics and other
medication, respectively. The total amount spent on
providing medication for these patients was R364 567.28,
which represented 7% of the total budget for medication in
the financial year 2001/2002.
ADMISSION COSTS FOR HIV+ INPATIENTS
Table V summarises the details of the admission costs for
HIV+ inpatients at RCH. The combined duration of stay (ICU
+ high care) was more than twice as long as that for all the
other inpatients at RCH (9 days v. 4.03 days). The amount
of time spent in the high-care wards differed tremendously
among HIV+ patients, hence the range of 107 days for time
spent in high care versus a relatively low range of 11 days 
for time spent in the ICU. Total admission costs amounted
to approximately R9.64 million, which formed 84% of the
total direct costs for HIV+ inpatients.
Approximately 12% of HIV+ patients admitted to RCH
spend time in the ICU. Fig. 6 shows that 61% of these
patients spend less than 1/3 of the total admission time in
Fig. 4. Nutritional status at admission of HIV-positive patients.
Average duration of stay in ICU 3.89
Average duration of stay (high care + ICU = total stay) 9
Average duration of stay for ALL patients 4.03
TABLE III. AVERAGE LENGTH OF STAY IN HOSPITAL (DAYS)
FOR HIV+ PATIENTS VERSUS ALL ADMISSIONS TO RCH




Total antibiotic cost for HIV 265.96 x 616 R163 831.36
Budgeted total for antibiotics (A/B) R1 352 645
Percentage of A/B budget consumed by 
HIV+ patients 12%
Anti-fungal costs
Mean cost per patient R136.72
Total 136.72 x 616 R84 219.52
Budgeted amount for antifungals R138 750
Percentage of budget consumed by 
HIV+ inpatients 61%
Analgesic costs
Mean cost per patient R20.63
Total spent on analgesics R12 708.08
Budgeted expenditure R140 787




Total spent R155 595.44




Total medication R364 567.28
Budget 7%
TABLE IV. MEDICATION COSTS FOR HIV+ INPATIENTS
the ICU and a relatively high percentage (33%) spend
between 1/3 and 2/3 of their total admission time in the
ICU. Six per cent of HIV+ patients spend more than 2/3 of
their total stay at RCH in the ICU.
AVERAGE AND TOTAL DIRECT COSTS FOR HIV+
INPATIENTS 
Fig. 7 provides information on the direct costs of treatment
for HIV+ inpatients at RCH. The average admission cost per
patient was R15 652.20, which formed 84% of the total
direct costs for HIV+ inpatients at RCH. Laboratory services
accounted for 9% (R1 677.42 per HIV+ patient) of the total
direct costs, medication costs for 3% (R596.76 per patient),
and surgical costs (R2 954.11 per patient) and X-rays
(R470.00 per patient) together for the remaining 4%. 
To obtain the total direct cost for all HIV+ patients
admitted to RCH during 2001, the average cost per
component, as shown in Fig. 5, was multiplied by 616 
(N = 616). This cost is reflected in Fig. 8 below as R11.56
million rands. The total direct cost for treating all patients
at RCH (R44.5 million rands) was obtained as follows:
The direct cost for HIV- patients (R33.09 million) was
calculated by subtracting the total direct cost for all
patients from the total direct costs for HIV+ patients
(R44.65 million - R11.56 million).
Alarmingly, HIV+ patients, who formed only 4% of total
admissions at RCH in 2001, consumed 26% of the total
budget for direct costs for patient treatment.
The proportion of HIV+ inpatients against total patient
intake for 2001 was relatively low at 4%. This low
percentage is similar to prevalence figures reported by
Madhi et al.17 who found that 5% of children born in
Soweto were HIV+.  However, the 4% prevalence rate
differs significantly from the findings of Leary,21 who
reported that 25% of general paediatric beds at RCH were
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Fig. 6. Duration of stay in ICU versus total admission time.
Fig. 7. Average cost per HIV+ inpatient (R).
DISCUSSION
Budgeted item 2001/2002 Cost as per budgeted
Total budget R152 840 000.00
Personnel expenditure -106 318 000.00
Administration expenses -1 291 000.00
Professional and 
special expenses -5 080 000.00
Revenue +4 500 000.00
Total direct costs R44 651 000.00






Average admission cost per patient 
in high care R14 456.37






Average admission cost per 
patient in ICU R10 231.67
Percentage of patients   
admitted to ICU 11.70%
Total admission costs per 
HIV+ patient R9 641 804.48
Average admission cost (high care
+ ICU) per HIV+ patient R15 652.28
TABLE V. DURATION AND COST OF STAY IN HOSPITAL
(HIV+ PAEDIATRIC PATIENTS)
Fig. 8. Direct treatment costs for inpatients at RCH (R)
(2001/2002).
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occupied by infants and toddlers with AIDS. This figure of
25% is misleading as it reflects the percentage for HIV+
patients in the general ward for one day only (15 of the 56
patients in the general ward). The findings of our study,
which reports on prevalence of HIV+ admissions for a full
year (4%), are also lower than those reported by Roux et al.7
who found that 8.3% of the total beds available in the Cape
Metropole Region in the second week of March 1999 were
occupied by HIV+ paediatric patients (106 of the 1 264
beds). Again, the time period of this study (1 week) makes
the use of this value unreliable when compared with the
4% prevalence reported in this study. Also, Roux et al.7
considered patients HIV+ if they had a positive laboratory
test or had suspected physical signs of HIV infection but
their serological status was unknown. Our selection criteria
for this study were more rigid, which could probably
explain the difference in the findings between Roux et al.
and our study. Chintu et al.16 and Vetter et al.18 reported
prevalence rates of 28% (Lusaka, Zambia, 1991) and 8.2%
(Abidjan, Ivory Coast, 1992), respectively.
Almost 80% of patients (Fig. I) were admitted to RCH with
a history of diarrhoea and vomiting (42%) and pneumonia
(37%). These findings are similar to those reported in other
studies.7,16,22 More than 60% (Fig. 2) of the patients admitted
during 2001 were  first-time admissions to the hospital.
This figure is significantly higher than the 35% reported by
Roux et al.7 About 25% of the cohort had been admitted
two or more times previously, indicating the tremendous
burden that HIV+ patients can place on limited bed space
at RCH, which has approximately 262 beds available for all
patients. Roux et al.7 also reported a mean of 2.4 v. 2.0 (our
study) admissions for those who had previous admissions
to hospital — however, at the time of the study patients did
not have access to ARV drugs that are routinely available in
most of the developed world.   
The average length of stay for HIV+ patients was 9 days per
patient, which is more than double the average for HIV-
patients (4.03). This translates to 12% of the total bed days
available at RCH (262 beds x 12 months x 30 days = 
94 320 000 theoretically available — assuming that these
beds are available all year round). In reality this figure of
12% will be higher as all hospitals in the Western Cape are
forced to reduce the number of beds available to reduce
costs and stay within their allocated budgets. Nelson et al.13
reported a mean length of stay for their patient cohort of
7.9 days.
Fig. 4 provides the details on most common conditions that
afflict HIV+ patients and cause them to be admitted to
hospital. The percentages may vary among different
studies, but most authors7,13,16,18 report similar diagnoses in
settings where ARV therapy is not available. Chan et al.23
reported that 25% of their HIV+ cohort were diagnosed
with TB. These findings are similar (Roux et al.7 21%, our
study 22%) to studies done locally, even though Chan’s
cohort of patients were in a setting (Children’s Medical
Center, Brooklyn, New York) where ARVs were available as
standard care. A key reason for the susceptibility of these
children to opportunistic infections is malnutrition, which
affected 87% of the patients in this study (Fig. 5). The
effects of living in abject poverty, often in households with
no proper sanitation or clean water, and in rural settings
where access to care is limited by the ability to pay for
transport, plays an important role in further complicating
the ability of these patients to ward off infections. The
story that is not told in this research paper is the cycle of
admission to hospital of very sick patients, their
‘stabilisation’ in hospital by overworked staff, their early
discharge (as soon as they are stabilised) back into the cycle
of poverty, and then their re-entry into hospital when they
are once more sick because of exposure to a hostile
environment that offers little chance for their well-being.
Some patients are eventually abandoned or referred to
places of safety because the parents themselves are sick
(or dead) and cannot care for their young. RCH also has to
bear the full cost of treatment of these patients as their
parents cannot afford to pay for health services. One
hundred per cent of the sample randomly selected for this
study were found under the ‘free patient’ category, which
exempted them from any payment for services rendered. 
The mortality rate of the cohort in this study was 8%. This
figure is significant when compared with the overall death
rate at RCH for the similar period (8% v. 1.7%). HIV+
patients were 4.7 times more likely to die in hospital than
their HIV- counterparts. Mortality rates from studies in
Ivory Coast18 (20.8% v. 8.7%) and Zambia16 (19% v. 9%) are
similar to those of RCH. Nelson et al.13 reported a mortality
rate of 16% for their cohort of patients in Malawi. Hussey
et al.9 examined the survival patterns of children known to
be vertically infected with HIV-1 in the Cape Town
Metropole. The median age at diagnosis was found to be 5
months — 72% of the children were less than a year old
when they were diagnosed with HIV. The median survival
time of children with HIV was 32 months from the time of
diagnosis. In developed countries, the median survival time
was found to be in excess of 5 years (60 months),24,25 which
was more than twice that for developing countries.9,26,27
Hussey et al.9 believe that the difference in survival is
clearly related to the availability and accessibility of
medical and other supportive care. 
The average direct cost to RCH to treat HIV+ patients was
found to be R18 765.76 per admission per HIV+ patient.
Eighty four per cent of this cost consisted of admission
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(bed) cost alone (Fig. 7). Mkele et al.28 reported in their cost
analysis for HIV+ patients that bed costs comprised 82% of
the total expense of inpatient care, while drugs made up
only 5%, results similar to those obtained in our survey. The
total amount spent on direct treatment costs for HIV+
inpatients amounted to 26% of the total direct costs for all
admissions to hospital, i.e. HIV+ patients, who accounted
for only 4% of total admissions to hospital, consumed 26%
of the budget for direct treatment costs. It is the view of
the authors that RCH is faced with tough choices if it
wants to operate within its allocated yearly budget.
Hospitals are being forced to operate within budgets and
managers at these institutions will have to take the
necessary steps (cost-cutting exercises) to make sure that
they do so. This then begs the question: What are the
options available to RCH in light of the ever-increasing HIV
epidemic, reduced budgets, greater demand for bed space,
over-worked staff and the continued inability of most
patients to pay for services?
1. DEVELOP QUOTAS FOR ADMISSION OF CERTAIN
CATEGORIES OF PATIENTS
To ensure that admission to RCH is available to the wider
spectrum of patients, categories of patients that use up a
higher amount of resources would have to be restricted.
However, this is fraught with ethical dilemmas, and doctors
will be forced to ‘play God’ with patients’ lives. In addition,
solutions would have to be found for those patients that
the hospital refuses to admit if it has exceeded its intake
quota for that category of patient. 
2. DEVELOP MANAGEMENT PROTOCOLS FOR IN-
HOSPITAL CARE OF HIV+ PATIENTS
There was a wide variation in terms of the direct costs
assessed in this study. While a lot of this variation can be
explained by the HIV+ patients admitted requiring different
levels or types of care, medication, laboratory tests and
surgical procedures discrepancies need to be addressed.
■ Some patients were discharged as soon as they were
‘stabilised’, as there was pressure in the ward for bed
space. Others were kept in hospital until they had fully
and completely recovered. 
■ Some patients were discharged with 3 months’ supply
of medicines and multivitamins. Other patients, who
appeared to need these medicines as they were
discharged as soon as they were stabilised, were not
given any medicines.
■ Some doctors appeared to keep patients in hospital
longer than others. This may be due to patient
circumstances, but is probably due to a more cautious
approach among certain doctors. 
3. PROVISION OF ANTIRETROVIRAL THERAPY (ART)
FOR HIV+ PATIENTS
The findings of this study provide strong evidence that
unless something is done to reduce the transmission rates
from mother to child, RCH will be faced with a greater
demand for bed space from HIV+ patients who require
more resources than other patients. In the USA and Brazil,
highly active antiretroviral therapy (HAART) was found to
reduce costs by an average of 46% and 80% for public
health hospitals.29 There is a shift of costs from
hospitalisation to outpatient care. In the local context, this
would imply the supply of cheaper HAART to reduce
hospitalisation and number of admissions.
4. PREVENTION OF MOTHER-TO-CHILD
TRANSMISSION (MTCT)
The Western Cape government has been involved in
preventive MTCT programmes since 1999. Every R1 spent in
the MTCT programme results in a saving of about R2.50 in
hospital costs for treating an HIV-positive baby. By
assuming that a single dose of nevirapine given within 72
hours after birth reduces transmission by 50%,30 one can
estimate that the proportion of HIV+ patients will be
reduced by a similar figure. This translates to the number of
inpatients diagnosed with HIV infection being reduced
from 616 to about 308. The total direct cost for treating
this group would then be around R5.77 million (R18 765.76
x 308) — a saving of R5.79 million (R18 765.76 x 308). This
saving is immense when compared with the price of a
single dose of nevirapine — about R10.31 Roux et al.7
calculated the lifetime cost of an HIV-infected child to be
almost twice that of protecting an infant from infection
through the prevention of MTCT.   
5. HOME-BASED CARE INITIATIVES
The flood of HIV+ patients into tertiary hospitals (such as
RCH) can be stemmed if there were more rural clinics and
home-based care linked to these specialist HIV clinics.22
Currently RCH, via its outpatient facilities, fulfils tertiary,
provincial, district and primary health care functions,
forcing highly trained staff often to spend too much time
on patients who do not necessarily require their skills.
Government needs to allocate more money for home-
based care initiatives and provide more nurses and doctors
in rural areas. A large majority (over 65%) of patients in this
study were from rural areas. Local communities should be
empowered to take charge of their own health care, and
basic skills transfer and visits to these communities by
trained nurses can result in much less suffering for patients
and less expense for the state which bears the full cost for
their care. 
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This study highlights the high cost of care that is required
by HIV+ patients who are admitted as inpatients to RCH.
RCH provides a beacon of hope for all children throughout
Africa, as it provides highly specialised care that is often
only available at this facility. However, it too is being
affected by the HIV crisis facing the country,  and is facing
an untenable position of continuing to provide specialised
care in an environment of lower budgets, higher demand
and greater need by children, who, along with their HIV+
mothers, continue to suffer discrimination. 
The managers of RCH face difficult choices requiring tough
decisions that must clearly be addressed with some
urgency. Decisions affecting the care of HIV-positive
children must reflect choices that are sustainable, and
furthermore must reflect our commitment to improving
the quality of life of these children. Government must be
informed that in a realistic economic sense, the pursuit of
efficient practice is not merely reducing costs or budgets or
avoiding costs.
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